The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results